-
EP3008092
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP3008092
| EP3008092 - TARGETING TUMOR NEOVASCULATURE WITH MODIFIED CHIMERIC ANTIGEN RECEPTORS [Right-click to bookmark this link] | Status | The application is deemed to be withdrawn Status updated on 15.12.2017 Database last updated on 02.09.2024 | |
| Former | Request for examination was made Status updated on 31.08.2017 | Most recent event Tooltip | 15.12.2017 | Application deemed to be withdrawn | published on 17.01.2018 [2018/03] | Applicant(s) | For all designated states The University Of Houston System 316 E. Cullen Building Houston, TX 77204-2015 / US | [2016/16] | Inventor(s) | 01 /
ZHANG, Xiaoliu 3231 South Pemberton Circle Drive Houston, TX 77025 / US | 02 /
FU, Xinping 4301 Willowbend Blvd. Houston, TX 77035 / US | [2016/16] | Representative(s) | J A Kemp LLP 80 Turnmill Street London EC1M 5QU / GB | [N/P] |
| Former [2016/16] | Bentham, Andrew J A Kemp 14 South Square Gray's Inn London WC1R 5JJ / GB | Application number, filing date | 14811656.9 | 13.06.2014 | [2016/16] | WO2014US42239 | Priority number, date | US201361835147P | 14.06.2013 Original published format: US 201361835147 P | [2016/16] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2014201319 | Date: | 18.12.2014 | Language: | EN | [2014/51] | Type: | A1 Application with search report | No.: | EP3008092 | Date: | 20.04.2016 | Language: | EN | The application published by WIPO in one of the EPO official languages on 18.12.2014 takes the place of the publication of the European patent application. | [2016/16] | Search report(s) | International search report - published on: | US | 18.12.2014 | (Supplementary) European search report - dispatched on: | EP | 09.12.2016 | Classification | IPC: | C07K16/30 | [2016/16] | CPC: |
A61K45/06 (EP,US);
A61K35/17 (US);
A61K38/195 (EP,US);
A61K39/461 (EP);
A61K39/4611 (EP);
A61K39/4631 (EP);
A61K39/464406 (EP);
A61P35/00 (EP);
A61K2239/26 (EP);
| C-Set: |
A61K38/195, A61K2300/00 (EP,US)
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2016/16] | Title | German: | ABZIELUNG AUF TUMORNEOVASKULATUR MIT MODIFIZIERTEN CHIMÄREN ANTIGENREZEPTOREN | [2016/16] | English: | TARGETING TUMOR NEOVASCULATURE WITH MODIFIED CHIMERIC ANTIGEN RECEPTORS | [2016/16] | French: | CIBLAGE DE LA NÉOVASCULARISATION TUMORALE AU MOYEN DE RÉCEPTEURS D'ANTIGÈNES CHIMÈRES MODIFIÉS | [2016/16] | Entry into regional phase | 17.12.2015 | National basic fee paid | 17.12.2015 | Search fee paid | 17.12.2015 | Designation fee(s) paid | 17.12.2015 | Examination fee paid | Examination procedure | 17.12.2015 | Examination requested [2016/16] | 25.07.2016 | Amendment by applicant (claims and/or description) | 14.07.2017 | Application deemed to be withdrawn, date of legal effect [2018/03] | 29.08.2017 | Despatch of communication that the application is deemed to be withdrawn, reason: reply to the communication from the examining division not received in time [2018/03] | Fees paid | Renewal fee | 31.03.2016 | Renewal fee patent year 03 | 08.06.2017 | Renewal fee patent year 04 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [Y] - Xiaoliu Zhang, "Exploration of synergistic effects by using a combination of two novel antitumor agents and nano-delivery vehicle to effectively treat resistant solid tumors", (20130312), URL: https://web.archive.org/web/20130312081221/http://www.cprit.state.tx.us/files/funded-grants/RP130553.pdf, (20161125), XP055323079 [Y] 1-15 * abstract * | [Y] - MAKRILIA N ET AL, "The role of angiogenesis in solid tumours: An overview", EUROPEAN JOURNAL OF INTERNAL MEDICINE, ELSEVIER, AMSTERDAM, NL, vol. 20, no. 7, doi:10.1016/J.EJIM.2009.07.009, ISSN 0953-6205, (20091101), pages 663 - 671, (20090827), XP026673823 [Y] 1-15 * the whole document * DOI: http://dx.doi.org/10.1016/j.ejim.2009.07.009 | International search | [A]US2009257952 (COCHRAN JENNIFER R [US], et al); | [Y]WO2012138858 (BAYLOR COLLEGE MEDICINE [US], et al); | [A]US2013040836 (HIMMLER GOTTFRIED [AT], et al); | [X] - FU ET AL., "Genetically modified T cells targeting neovasculature efficiently destroy tumor blood vessels, shrink established solid tumors and increase nanoparticle delivery", INTERNATIONAL JOURNAL OF CANCER, (20130510), vol. 133, no. 10, pages 2483 - 2492, XP055299259 DOI: http://dx.doi.org/10.1002/ijc.28269 | [A] - WIERZBICKA-PATYNOWSKI ET AL., "Structural Requirements of Echistatin for the Recognition of alphavbeta3 and alpha5beta1 Integrins", THE JOURNAL OF BIOLOGICAL CHEMISTRY, (19991231), vol. 274, no. 53, pages 37809 - 37814, XP002452289 DOI: http://dx.doi.org/10.1074/jbc.274.53.37809 |